Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.48 |
| ▸ | CCNA2 | P20248 | 9/20 | 0.48 |
| ▸ | CDK2 | P24941 | 9/20 | 0.48 |
| ▸ | MAPT | P10636 | 6/20 | 0.48 |
| ▸ | CDK5 | Q00535 | 4/20 | 0.48 |
| ▸ | CDK5R1 | Q15078 | 4/20 | 0.48 |
| ▸ | NPC1 | O15118 | 4/20 | 0.48 |
| ▸ | RAB9A | P51151 | 4/20 | 0.48 |
| ▸ | GSK3A | P49840 | 1/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.40 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1249311 | 0.87 | MAPT (0.37) | GSK3BCCNA2CDK2MAPTCDK5 | |
| SCHEMBL7756995 | 0.77 | MAPT (0.68) | GSK3BCCNA2CDK2MAPTCDK5 | |
| SCHEMBL6609305 | 0.72 | MAPT (0.30) | CCNA2CDK2MAPT | |
| SCHEMBL5553339 | 0.70 | MAPT (0.51) | GSK3BCCNA2CDK2MAPTCDK5 | |
| SCHEMBL1248421 | 0.69 | CCNA2 (0.49) | GSK3BCCNA2CDK2MAPTCDK5 | |
| SCHEMBL1250757 | 0.68 | MAPT (0.52) | GSK3BCCNA2CDK2MAPTCDK5 | |
| SCHEMBL6754732 | 0.68 | CCNA2 (0.43) | CCNA2CDK2CDK5CDK5R1 | |
| SCHEMBL7753436 | 0.68 | CCNA2 (0.76) | GSK3BCCNA2CDK2MAPTCDK5 | |
| SCHEMBL7757552 | 0.68 | CCNA2 (0.76) | GSK3BCCNA2CDK2MAPTCDK5 | |
| SCHEMBL27742183 | 0.68 | MAPT (0.48) | GSK3BCCNA2CDK2MAPTCDK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090312390-A1 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3 (GSK-3) FOR TREATING GLAUCOMA | ALCON, INC. (CH) | 2009-12-17 | — | — | US | claimed |
| EP-1430120-A4 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3 (GSK-3) FOR TREATING GLAUCOMA | ALCON INC (CH) | 2007-06-20 | — | — | EP | claimed |
| US-20040186159-A1 | Inhibitors of glycogen synthase kinase-3 (gsk-3) for treating glaucoma | NOVARTIS AG (CH) | 2004-09-23 | — | — | US | claimed |
| EP-1430120-A1 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3 (GSK-3) FOR TREATING GLAUCOMA | Alcon, Inc. (CH) | 2004-06-23 | — | — | EP | claimed |
| WO-2003027275-A1 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3 (GSK-3) FOR TREATING GLAUCOMA | ALCON, INC. (CH) | 2003-04-03 | — | — | WO | claimed |
| EP-2281560-A1 | Inhibitors of glycogen synthase kinase-3 (GSK-3) for treating glaucomatous optic neuropathy | Alcon, Inc. (CH) | 2011-02-09 | — | — | EP | disclosed |
| US-20090312390-A1 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3 (GSK-3) FOR TREATING GLAUCOMA | ALCON, INC. (CH) | 2009-12-17 | — | — | US | disclosed |
| US-7598288-B2 | Inhibitors of glycogen synthase kinase-3 (GSK-3) for treating glaucoma | ALCON, INC. (CH) | 2009-10-06 | — | — | US | disclosed |
| EP-1430120-A4 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3 (GSK-3) FOR TREATING GLAUCOMA | ALCON INC (CH) | 2007-06-20 | — | — | EP | disclosed |
| US-20040186159-A1 | Inhibitors of glycogen synthase kinase-3 (gsk-3) for treating glaucoma | NOVARTIS AG (CH) | 2004-09-23 | — | — | US | disclosed |
| EP-1430120-A1 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3 (GSK-3) FOR TREATING GLAUCOMA | Alcon, Inc. (CH) | 2004-06-23 | — | — | EP | disclosed |
| WO-2003027275-A1 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3 (GSK-3) FOR TREATING GLAUCOMA | ALCON, INC. (CH) | 2003-04-03 | — | — | WO | disclosed |
| US-20010039275-A1 | Use of 2,4-diaminothiazole derivatives | NOVO NORDISK A/S (DK) | 2001-11-08 | — | — | US | disclosed |
| WO-2001056567-A1 | 2,4-DIAMINOTHIAZOLE DERIVATIVES AND THEIR USE AS GLYCOGEN SYNTHASE KINASE-3 (GSK-3) INHIBITORS | NOVO NORDISK A/S (DK) | 2001-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186159-A1 | Inhibitors of glycogen synthase kinase-3 (gsk-3) for treating glaucoma | GSK3B, GSK3A, GSKIP | GSK3B 1/4885CCNA2 4260/4885CDK2 1208/4885 |
| US-20090312390-A1 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3 (GSK-3) FOR TREATING GLAUCOMA | GSK3B, GSK3A, GSKIP | GSK3B 1/4885CCNA2 4260/4885CDK2 1208/4885 |
| US-20010039275-A1 | Use of 2,4-diaminothiazole derivatives | GSK3A, GSK3B, GSKIP | GSK3B 2/4885CCNA2 3738/4885CDK2 566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.